Key clinical point: Adjunctive brexpiprazole had a modest yet significant positive effect on several components of sexual functioning in women with major depressive disorder (MDD).
Major finding: At 6 weeks (short term) and 52 weeks (long term), adjunctive brexpiprazole numerically improved all Massachusetts General Hospital Sexual Functioning Questionnaire items. The improvement with brexpiprazole vs. placebo was significant for interest (P = .0074), arousal (P = .0154), and overall satisfaction (P = .0184).
Study details: Analysis of short-term and long-term studies on MDD patients with inadequate response to antidepressants treated with adjunctive brexpiprazole.
Disclosures: The trial was funded by Otsuka Pharmaceutical Development & Commercialization Inc and H. Lundbeck A/S. A Clayton received grants/support from various sources. J Ivkovic is a full-time employee of H. Lundbeck A/S. D Chen, V George, and M Hobart are full-time employees of Otsuka Pharmaceutical Development & Commercialization Inc.
Clayton AH et al. J Clin Psychopharmacol. 2020;40(6):560-56. doi: 10.1097/JCP.0000000000001297.